Xavier RCMI Renewal Application-Research Infrastructure Core
Xavier RCMI Renewal Application-Research Infrastructure Core
批准号:
10544048
负责人:
Vladimir Kolesnichenko
金额:
$116.67万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-24 至 2023-09-19
关键词:
Applications GrantsAreaBackBehaviorBioinformaticsBiomedical ResearchBiometryCellular biologyChargeCollaborationsCommunitiesCore FacilityDataDevelopmentDrug Delivery SystemsDrug FormulationsElectrophoresisEquilibriumEquipmentExperimental DesignsFacultyFeesFees and ChargesFundingGoalsHealthInstitutionInstitutionalizationInvestigationJointsLaboratoriesMalignant NeoplasmsMeasuresMicroscopeMolecular BiologyNCI Center for Cancer ResearchPilot ProjectsProceduresProcessProductivityPublic Health InformaticsRecoveryResearchResearch InfrastructureResearch MethodologyResearch PersonnelResearch Project GrantsResourcesReverse Transcriptase Polymerase Chain ReactionServicesSpectrophotometrySystemTechniquesTimecancer health disparitycomputerized data processingcostdrug discoveryexperimental studyimprovedinstrumentinstrumentationmemberoperationprogramsrepairedsenior facultystatisticstool
中文摘要
研究基础设施核心概述
RCMI癌症研究中心旨在提高泽维尔基础生物医学的质量和生产力。
和行为研究的重点领域,癌症和癌症相关的健康差距,建立一个
研究基础设施核心(RIC)将共享仪器,药物发现和交付
程序,细胞和分子生物学设施,以及生物信息学服务。现有核心资源的基础是
前三个RCMI核心实验室为Xavier研究人员提供服务,并帮助扩大研究
能力在过去十年。基于对当前研究的优势和劣势的评估
Xavier调查员组合,RIC将实施新的优先级规则,修订和改进
标准化运作程序,以及更有效的核心设施管理,包括
跨学科专业知识和成本回收系统。RIC将最大限度地使Xavier研究人员受益
在所有与健康相关的研究领域,通过实现三个具体目标:目标1。获取、维护和
操作共享的分析和生物分析仪器,不仅用于基础生物医学,
研究项目和试点项目,以资助目前的RCMI申请,而且所有泽维尔
研究人员在广泛的健康相关的研究领域。RIC将提供必要的
Xavier生物医学研究项目的仪器和技术支持,这些项目依赖于
主要设备运行。目标2.形成一个教师专业小组(FEG),提供教师级的专业知识,
研究方法、专门实验室技术、统计、生物信息学和卫生信息学。的
FEG将由在实验设计和研究方面具有研究专长的高级教师组成
药物发现和配方、细胞和分子生物学、机制研究和数据策略
使用各种生物信息学和生物统计学工具处理药物发现、药物递送、细胞和分子
生物学、生物信息学和分析仪器。目标3.实施有效的成本回收计划,
研究基础设施核心。RIC将继续使用2012年开始的收费系统。FEG将
监督退款流程并维护账户余额。所收取的费用将继续用于
部分支付核心设施所需的消耗性部件费用和意外维修费用。
将采取额外措施,通过承保核心工作人员,增加核心设施的成本回收
Xavier研究人员在外部赠款申请方面的努力。
英文摘要
Summary of Research Infrastructure Core
The RCMI Cancer Research Center aims to enhance the quality and productivity of Xavier’s basic biomedical
and behavior research in the focus area of cancer and cancer-related health disparities by establishing a
Research Infrastructure Core (RIC) that will have shared instrumentation, drug discovery and delivery
programs, cell and molecular biology facilities, and bioinformatics services. The current core resources build on
the previous three RCMI core laboratories that served Xavier investigators and helped expand the research
capacity in the last decade. Based on the assessment of strengths and weaknesses in the current research
portfolio of Xavier investigators, the RIC will implement new rules of prioritization, revised and improved
standard operation procedures, and more effective management of core facilities including convergence of
cross disciplinary expertise and cost recovery systems. The RIC will maximally benefit Xavier investigators
across all health-related research areas by achieving three specific aims: Aim 1. Acquire, maintain, and
operate shared analytical and bioanalytical instrumentation that will be utilized by not only the basic biomedical
research projects and pilot projects to be funded by the current RCMI application, but also all Xavier
investigators across a broad range of health-related research areas. The RIC will provide essential
instrumental and technical support for Xavier’s biomedical research projects that rely on the availability of
functioning major equipment. Aim 2. Form a faculty expertise group (FEG) to provide faculty-level expertise in
research methodology, specialized laboratory techniques, statistics, bioinformatics and health informatics. The
FEG will consist of senior faculty members with research expertise in experimental design and research
strategy on drug discovery and formulation, cell and molecular biology, mechanistic investigations, and data
processing using various bioinformatics and biostatistics tools drug discovery, drug delivery, cell and molecular
biology, bioinformatics, and analytical instrumentation. Aim 3. Implement an effective cost recovery program for
the Research Infrastructure Core. RIC will continue to use a fee charging system started in 2012. The FEG will
oversee the charge back process and maintain account balance. The fees collected will continue to be used to
partially defray the cost of consumable parts and unexpected repair costs needed for the core facilities.
Additional measures will be implemented to increase cost recovery of core facilities by underwriting core staff
efforts in external grant applications by Xavier investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NANOPARTICLES OF MAGNETIC IRON OXIDES AS PROSPECTIVE DIAGNOSTIC AGENTS
-
批准号:8357086
-
项目类别:
-
资助金额:$11.82万
-
财政年份:2011
-
负责人:Vladimir Kolesnichenko
-
依托单位:
NANOPARTICLES OF MAGNETIC IRON OXIDES AS PROSPECTIVE DIAGNOSTIC AGENTS
-
批准号:8166224
-
项目类别:
-
资助金额:$13.74万
-
财政年份:2010
-
负责人:Vladimir Kolesnichenko
-
依托单位:
Xavier RCMI Renewal Application-Research Infrastructure Core
-
批准号:10322699
-
项目类别:
-
资助金额:$83.92万
-
财政年份:2009
-
负责人:Vladimir Kolesnichenko
-
依托单位:
Xavier RCMI Renewal Application-Research Infrastructure Core
-
批准号:10078880
-
项目类别:
-
资助金额:$102.55万
-
财政年份:2009
-
负责人:Vladimir Kolesnichenko
-
依托单位:
RCMI Research Capacity Core
-
批准号:10800565
-
项目类别:
-
资助金额:$145.1万
-
财政年份:2009
-
负责人:Vladimir Kolesnichenko
-
依托单位:
Xavier RCMI Renewal Application-Research Infrastructure Core
-
批准号:9889176
-
项目类别:
-
资助金额:$130.18万
-
财政年份:--
-
负责人:Vladimir Kolesnichenko
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: